332 related articles for article (PubMed ID: 27748765)
1. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
Harrod A; Fulton J; Nguyen VTM; Periyasamy M; Ramos-Garcia L; Lai CF; Metodieva G; de Giorgio A; Williams RL; Santos DB; Gomez PJ; Lin ML; Metodiev MV; Stebbing J; Castellano L; Magnani L; Coombes RC; Buluwela L; Ali S
Oncogene; 2017 Apr; 36(16):2286-2296. PubMed ID: 27748765
[TBL] [Abstract][Full Text] [Related]
2. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
3. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
5. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
[TBL] [Abstract][Full Text] [Related]
6. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
8. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
10. Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.
Held JM; Britton DJ; Scott GK; Lee EL; Schilling B; Baldwin MA; Gibson BW; Benz CC
Mol Cancer Res; 2012 Aug; 10(8):1120-32. PubMed ID: 22669764
[TBL] [Abstract][Full Text] [Related]
11. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
12. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
14. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
[TBL] [Abstract][Full Text] [Related]
15. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
16. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192
[TBL] [Abstract][Full Text] [Related]
17. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
18. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Harrod A; Lai CF; Goldsbrough I; Simmons GM; Oppermans N; Santos DB; Győrffy B; Allsopp RC; Toghill BJ; Balachandran K; Lawson M; Morrow CJ; Surakala M; Carnevalli LS; Zhang P; Guttery DS; Shaw JA; Coombes RC; Buluwela L; Ali S
Oncogene; 2022 Oct; 41(44):4905-4915. PubMed ID: 36198774
[TBL] [Abstract][Full Text] [Related]
19.
Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
